TITLE

Number Needed to Treat for Recurrent Events

AUTHOR(S)
Cook, Richard J.
PUB. DATE
May 2013
SOURCE
Journal of Biometrics & Biostatistics;2013, Vol. 4 Issue 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Many clinical investigators find the Number Needed to Treat (NNT) an appealing measure of treatment effect and use it routinely in reporting the results of randomized trials. It is most easily computed and interpreted for trials with binary responses, but attempts have been made to compute NNT-like measures for recurrent event outcomes. We discuss methodological issues concerning the construction of NNT-like measures of treatment effect based on recurrent event outcomes. Rate and mean functions are used to develop nonparametric estimates of NNT-like measures of treatment effect for recurrent events in terms of the number of individuals to be treated to expect to prevent a kth event, and simply to prevent any event. Parametric analyses facilitate the derivation of alternative measures and associated estimates. Applications to a trial of patients with cystic fibrosis are given for illustration. In settings where mortality rates are non-negligible, joint NNT-like measures for the recurrent event and survival processes are required and these are discussed.
ACCESSION #
89712262

 

Related Articles

  • Airway clearance research in CF: the 'perfect storm' of strong preference and effortful participation in long-term, non-blinded studies. Main, Eleanor // Thorax;Aug2013, Vol. 68 Issue 8, p701 

    The author discusses a study by M. McIlwaine and coworkers conducted to examine patient preference for airway clearance technique in the treatment of cystic fibrosis (CF). Topics include long term randomised controlled trial (RCT), patients preference and dropouts during the trial, and need for...

  • Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. Kaufman, Michael; Cree, Bruce; Sèze, Jerome; Fox, Robert; Gold, Ralf; Hartung, Hans-Peter; Jeffery, Douglas; Kappos, Ludwig; Montalbán, Xavier; Weinstock-Guttman, Bianca; Ticho, Barry; Duda, Petra; Pace, Amy; Campagnolo, Denise // Journal of Neurology;Feb2015, Vol. 262 Issue 2, p326 

    The objective of this study is to characterize the timing and extent of radiologic MS disease recurrence during the 24-week natalizumab treatment interruption period in RESTORE. RESTORE was a randomized, partially placebo-controlled exploratory study. Natalizumab-treated patients with no...

  • Cost of cystic fibrosis increases with worsening severity.  // PharmacoEconomics & Outcomes News;9/1/2012, Issue 661, p5 

    The article discusses research on the treatment costs of cystic fibrosis (CF) in relation to its severity, referencing a study by M. Heimeshoff and colleagues published in a 2012 issue of "PharmacoEconomics."

  • A Lesson in Participatory Research for a Rare Mutation of Cystic Fibrosis. Kramer-Golinkoff, Emily // JGIM: Journal of General Internal Medicine;Aug2014 Supplement, Vol. 29, p808 

    A personal narrative is presented which explores the author's experience participating in a research for a rare mutation of cystic fibrosis (CF) to help find a cure for the disease through the Food and Drug Administration (FDA)-approved drug Ivacaftor.

  • A multiple comparison procedure for hypotheses with gatekeeping structure. Luo, Xiaolong; Chen, Guang; Ouyang, S. Peter; Turnbull, Bruce W. // Biometrika;Jun2013, Vol. 100 Issue 2, p301 

    We develop gatekeeping procedures that focus on comparing multiple treatments with a control when there are multiple endpoints. Our procedures utilize estimated correlations among individual test statistics without parametric assumptions. We make comparisons with other gatekeeping procedures...

  • Search for the Cure.  // Discover;Sep2013, Vol. 34 Issue 7, p45 

    A timeline is presented for the Cystic Fibrosis Foundation (CFF) nonprofit organization from its establishment in 1955 to 2013, with details on the research and development of drugs to treat the genetic disorder cystic fibrosis.

  • Aztreonam tops tobramycin in CF.  // PharmacoEconomics & Outcomes News;7/7/2012, Issue 657, p7 

    The article discusses research on the cost effectiveness of inhalation treatment with aztreonam compared with tobramycin in cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa infection, referencing a study by M. S. Schechter and colleagues published in the May 23, 2012 issue...

  • Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Abboud, Hesham; Petrak, Alex; Mealy, Maureen; Sasidharan, Sarana; Siddique, Laila; Levy, Michael // Multiple Sclerosis Journal;Feb2016, Vol. 22 Issue 2, p185 

    Background: Although adding plasma exchange (PLEX) to steroids in severe neuromyelitis optica (NMO) attacks is common practice in steroid-resistant cases, the benefit of this strategy has not been previously quantified. Objective: The objective of this paper is to compare the efficacy of...

  • Improving eficiency in cluster-randomized study design and implementation: taking advantage of a crossover. Reich, Nicholas G.; Milstone, Aaron M. // Open Access Journal of Clinical Trials;2014, Vol. 6, p11 

    While individually randomized trials have long provided the gold standard of clinical evidence, the use of cluster-randomized trials in biomedical and social scientific research has expanded rapidly in recent years. In certain settings, randomizing by group or cluster can provide distinct...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics